Cargando…

Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes

BACKGROUND: We aimed to identify the relationship between the genomic characteristics and clinical outcomes of oligo-metastatic breast cancer. METHODS: Oligo-metastatic breast cancer diagnosed by pathology from January 2001 and August 2019 were reviewed and we matched the poly-metastatic patients ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Kuikui, Zhou, Danyang, Xu, Fei, Xia, Wen, Zheng, Qiufan, Lu, Qianyi, Luo, Rongzhen, Hong, Ruoxi, Wang, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503038/
https://www.ncbi.nlm.nih.gov/pubmed/37715134
http://dx.doi.org/10.1186/s12885-023-10833-2
_version_ 1785106437786042368
author Jiang, Kuikui
Zhou, Danyang
Xu, Fei
Xia, Wen
Zheng, Qiufan
Lu, Qianyi
Luo, Rongzhen
Hong, Ruoxi
Wang, Shusen
author_facet Jiang, Kuikui
Zhou, Danyang
Xu, Fei
Xia, Wen
Zheng, Qiufan
Lu, Qianyi
Luo, Rongzhen
Hong, Ruoxi
Wang, Shusen
author_sort Jiang, Kuikui
collection PubMed
description BACKGROUND: We aimed to identify the relationship between the genomic characteristics and clinical outcomes of oligo-metastatic breast cancer. METHODS: Oligo-metastatic breast cancer diagnosed by pathology from January 2001 and August 2019 were reviewed and we matched the poly-metastatic patients based on the clinicopathological features of patients included. Clinicopathological values and data of genomic alterations were collected. Oligo-recurrence (oligo-R) was defined as a situation where disease progression occurred in less than 5 anatomical sites and other anatomic areas still suppressed by the ongoing therapy. RESULTS: A total of 26 breast cancer patients were enrolled in our study, including 14 patients with strict oligo-metastatic disease (oligo-R > 6 months) and 12 with simultaneous poly-metastatic disease. PIK3CA, TP53 and ERBB2 were the most common shared alterations identified in patients included. Based on the median time of oligo-R, we divided the patients with oligo-metastasis into longer oligo-R group (oligo-R > 31.04 months) and shorter oligo-R group (oligo-R ≤ 31.04 months). The analysis of PIK3CA mutation sites showed that H1047R mutation was closely associated with oligo-metastasis, rather than poly-metastasis. H1047R mutation also predicted a better prognosis (oligo-R > 31.04 months) in oligo-metastatic breast cancer. In addition, HER2 positive was more likely to be related to a good outcome in patients with oligo-metastasis. CONCLUSIONS: Through the genetic analysis of samples from oligo-metastasis, we found the prognostic values of PIK3CA H1047R and HER2 in oligo- and poly-metastasis. We improved the stratification of prognosis and provided new insights for biological behaviors of oligo-metastatic breast cancer.
format Online
Article
Text
id pubmed-10503038
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105030382023-09-16 Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes Jiang, Kuikui Zhou, Danyang Xu, Fei Xia, Wen Zheng, Qiufan Lu, Qianyi Luo, Rongzhen Hong, Ruoxi Wang, Shusen BMC Cancer Research BACKGROUND: We aimed to identify the relationship between the genomic characteristics and clinical outcomes of oligo-metastatic breast cancer. METHODS: Oligo-metastatic breast cancer diagnosed by pathology from January 2001 and August 2019 were reviewed and we matched the poly-metastatic patients based on the clinicopathological features of patients included. Clinicopathological values and data of genomic alterations were collected. Oligo-recurrence (oligo-R) was defined as a situation where disease progression occurred in less than 5 anatomical sites and other anatomic areas still suppressed by the ongoing therapy. RESULTS: A total of 26 breast cancer patients were enrolled in our study, including 14 patients with strict oligo-metastatic disease (oligo-R > 6 months) and 12 with simultaneous poly-metastatic disease. PIK3CA, TP53 and ERBB2 were the most common shared alterations identified in patients included. Based on the median time of oligo-R, we divided the patients with oligo-metastasis into longer oligo-R group (oligo-R > 31.04 months) and shorter oligo-R group (oligo-R ≤ 31.04 months). The analysis of PIK3CA mutation sites showed that H1047R mutation was closely associated with oligo-metastasis, rather than poly-metastasis. H1047R mutation also predicted a better prognosis (oligo-R > 31.04 months) in oligo-metastatic breast cancer. In addition, HER2 positive was more likely to be related to a good outcome in patients with oligo-metastasis. CONCLUSIONS: Through the genetic analysis of samples from oligo-metastasis, we found the prognostic values of PIK3CA H1047R and HER2 in oligo- and poly-metastasis. We improved the stratification of prognosis and provided new insights for biological behaviors of oligo-metastatic breast cancer. BioMed Central 2023-09-15 /pmc/articles/PMC10503038/ /pubmed/37715134 http://dx.doi.org/10.1186/s12885-023-10833-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jiang, Kuikui
Zhou, Danyang
Xu, Fei
Xia, Wen
Zheng, Qiufan
Lu, Qianyi
Luo, Rongzhen
Hong, Ruoxi
Wang, Shusen
Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
title Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
title_full Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
title_fullStr Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
title_full_unstemmed Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
title_short Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
title_sort genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503038/
https://www.ncbi.nlm.nih.gov/pubmed/37715134
http://dx.doi.org/10.1186/s12885-023-10833-2
work_keys_str_mv AT jiangkuikui geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes
AT zhoudanyang geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes
AT xufei geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes
AT xiawen geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes
AT zhengqiufan geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes
AT luqianyi geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes
AT luorongzhen geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes
AT hongruoxi geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes
AT wangshusen geneticanalysisofoligorecurrencebreastcancercorrelationwithclinicaloutcomes